AIkido Pharma Inc (AIKI)

[Taurus69]

$aiki $1.19 v -0.04 (-3.25%)
Volume: 13,189,558 @02/26/21 7:59:56 PM EST

[BugStocks_com]

AIKI mentioned in this Magic Mushroom article https://insiderfinancial.com/eight-mushroom-penny-stocks-causing-portfolios-to-go-psychedelic/181054/

[nuclear profitz]

On January 12, 2021, AIkido Pharma Inc., a Delaware corporation (the “Company”), reconvened its 2020 annual meeting of stockholders (the “Meeting”). At the Meeting, the Company’s did not obtain the approval from stockholders that held a majority of the issued and outstanding shares of common stock as of the record date that was set for determination of stockholders entitled to notice and to vote at the Meeting of the proposal to amend the Company’s amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”) to effect a reverse stock split of the Company’s common stock to a ratio of up to one-for-ten.


https://ih.advfn.com/stock-market/NASDAQ/alkido-pharma-AIKI/stock-news/84124954/current-report-filing-8-k

[nathanial]

I think the big boys are here now.

[BlindSquirrelFindsNuts]

47mm shares from the offering. Be about 80mm now but yeah they shouldn't need to RS from here. I think that was more relevant for Nasdaq when they were well below $1.00. $AIKI

[mick]

Alkido Pharma Inc (AIKI)
1.65 ? 0.11 (7.14%)
Volume: 42,949,565 @02/19/21 7:59:48 PM EST
Bid Ask Day's Range
1.64 1.65 1.56 - 1.75
AIKI Detailed Quote

[nathanial]

How can you R/S a stock with only 34 million outstanding. Leaves no float.

[nathanial]

I saw in the filings they extended the time because there were not enough votes to approve the reverse split in November. Moved it to January but can't find the outcome. This new influx of cash probably the reason for no reverse split in January.

[Billybob_TX]

There is a PR on my TOS TDA platform. Should be on about any platform out there. On mobile right now or I would post it.

[georgie18]

Gan,I play it csndle by candle so we shall see but I think first the gap in the $2 range needs to fill...enjoy...

[Gan]

georgi18, Thanks for your TA on this..
Holding a small position here since early Jan. It did not fill the gap in 0.90's and now have another gap upside to to fill (?) .. What's your short term target on this, $2.5 to $2.7? Since the company has raised $75M recently, hope they have some good stories to tell soon.
Good luck

[nathanial]

Is there any link, filing or PR stating shareholders voted against it? That would be a material event resulting in an 8K or something.
Thanks.

[STOCKSnGLOCKS]

10k @ 1.58 for me :)

[stockticks]

There was nearly a million totalled on the bid from 1.52 to 1.50 at the end of the day. Someone did not want this under 1.50. I would say we’re at the floor. Tomorrow the offering is complete. Should hopefully see a leg up from here. Cheers.

[FROZENFLAME]

$AIKI 18k@$1.55, I have a feeling tomorrow should be good

[Stockz12345]

Added 25k shares $1.57 hope this goes well :)

[mopartuck]

Took a position at 1.68. Watching to see where this one goes.

[ClayTrader]

* * $AIKI Video Chart 02-17-2021 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $AIKI Video Chart 02-17-2021 * *

Link to Video - click here to watch the technical chart video

[D-bol]

With you

[BluSkies]

75M for what!? They got like 3 - 4 people?

[georgie18]

AIKI...$1.70...back in here with a 10,000 share starter...will add accordingly up or down...:party:

[antman]

Don't see AIKI mentioned anywhere?

[billionsmatter]

Read it all looks like AIKI is getting more coverage from OTC TIP Reporter. The last time they covered it pre market 188 million shares traded.

Yahoo

Jan 06, 2021 1.4500 1.7500 1.0000 1.0400 1.0400 188,532,900
Jan 05, 2021 0.8400 0.8700 0.8100 0.8500 0.8500 4,682,800

Dear Fellow Trader,

Did you miss out on GameStop's Massive Run Up a Few Weeks Ago?

Do not worry, if you missed out on that one… But if you did, I have something for you.

...Keep reading, because I'm going to share a secret that Wall Street doesn't want you to know.

What happened to GameStop's stock happens all the time...

That’s right!

The rally was the result of a plain, old "short squeeze."

That's when traders that bet against a stock have to buy back their shares at a loss if the trade moves against them and moves up instead of down.

Now, the GameStop's "short squeeze" was spearheaded by an online trading forum called WallStreetBets.

That doesn't necessarily happen every day.

But "short squeezes" are common in the stock market — without any help from WallStreetBets traders.

And they’re one of our members' favorite types of trades.

So today, I'm going to show you how short squeezes work...

The Simple Story of the "Short Squeeze"

Before I get into the charts, historical prices and short interest...

Let’s talk about “short selling."

In order to bet against a stock, traders borrow shares from a shareholder and sell them into the market.

Short sellers, as these traders are called, make money if the stock goes down — and lose money if the stock goes up.

That's basically the opposite of long investing, where you buy a stock and hopefully sell it later at a higher price.

Sounds simple, right?

Well, here’s the fatal flaw of short selling.

There’s no limit to how much money you can lose if a short trade goes the wrong way.

And when too many short sellers crowd into a stock, it can be difficult for them to get out of their trades.

It gets better…

The more crowded a short trade, the faster and higher a stock can soar before the "shorts are squeezed out."

That's exactly what happened to GameStop...

And 'squeezes' happen on heavily shorted stocks all the time.

Feel bad about the short sellers who get crushed?

You shouldn’t!

Remember, that many of them are big, ol’ Wall Street firms with way more resources and research firepower than you’ll ever have.

And if they get 'squeezed' it's their own fault for taking on too much risk in the first place.

So How Can You Take Advantage

?of a "Short Squeeze?"

Immediately Turn Your Attention to SponsorsOne Inc. (SPONF)

(SPONF) could be setting up for another +354.29% Massive Gain like it did in January… We have detected a potential "short squeeze" in the making.


Before we dig into this huge Breakout Report, I’d like to take a minute to extend a “Huge Welcome” to all of our New Members and a “Big Thank You” to all of our Long-Time Loyal Readers who have witnessed some Massive Gainers.

And while we are at it, take a look at these...

RECENT GAINERS FROM 2021

January 12th, Global WholeHealth Partners Corporation alerted at $.49 ran to $2.17 on January 21st for Potential Gains of +342.86%

January 6th, AIkido Pharma Inc. alerted at ($.84 pre-market) ran to $2.39 on Friday Feb 12th for Potential Gains of +184.52%

January 4th, FDCTech Inc. alerted at $.475 ran to $.945 on February 10th for Potential Gains of +98.94%

January 19th, SponsorsOne Inc. alerted at $.0088 ran to $.0318 on January 26th for Potential Gains of +261.36% (Could be setting up for another Huge Run)??

February 8th, QSAM Biosciences Inc. alerted at $.85 ran to $1.09 on February 9th for Potential Gains of +28.24% (Not bad for one day)

Pull up (SPONF) Right Now and Start Your Research

As you can see from the Recent Gainers listed above, our alerts have been showing members some of Wall Street’s Biggest Gains.

The last time I alerted (SPONF), it ran for +261.36% in about one week.

?Below you can see a screenshot from BarChart.com, which shows the opening price on January 19th… and the high price on January 26th.


...To put this into perspective for you, a +261.36% run is like turning $2,000 into over $5,000 in less than a week… and I don’t know anyone who would want to miss out on a move like that...

Are We at the Beginning of Another

"Massive Short Squeeze?"

...Keep reading to see what I just discovered on (SPONF)

As I was doing my research I observed a simple pattern which could be indicating that a Massive Short Squeeze is about to send shares of (SPONF) Soaring…

You see, if you look at the screenshot below, on Wednesday Feb. 10th, the Short Volume on (SPONF)was 68.09% of the total session volume. This is the same setup we saw last month when on Jan. 19th, I alerted SPONF at $.0088 and it ran to $.0318 on Jan. 26th for Potential Gains of +261.36%.


If you pull up a chart on SPONF right now, you’ll notice that just a few days before it’s Massive Breakout and Huge Run Up, there were a few consecutive days in a row where the Short Volume was nearing 60% of the total trading volume. And Then BOOM! SPONF Shot Up Like a Rocket… Was that a Massive Short Squeeze that sent shares of SPONF Soaring?

Unless you’ve been living under a rock, you’ve likely heard about GameStop…

And the epic short squeeze put on major Wall Street hedge funds that was spearheaded by an online trading forum of retail traders.

Wall Street hedge funds and market makers were hoping to make a pro·fit off of GameStop stock falling, but legions of small-time traders pushed the game retailer’s stock higher creating “a short squeeze,” which forced those who bet against the shares to buy back in order to prevent bigger losses, sending the stock price even higher. This could be a potential catalyst for (SPONF).

As legions of small-time traders pushed the game retailer’s stock higher, institutional investors "were squeezed,” which caused them to lose money on their bet that the stock would decline.

To limit the damage, the hedge funds and market makers had to "buy GameStop (GME)shares," pushing the stock even higher. GameStop shares rocketed to more than 20 times the price they started the year at.

You need to start your research on (SPONF) Right Now and put it on your trading screen or you may end up missing out on another potential breakout.

Keep Reading to See Why I am Still so

Excited About (SPONF)

A talent stacked team led by President & CEO Myles Bartholomew, SponsorsOne (SPONF) is a company that utilizes its proprietary platform that combines digital marketing, wholesale and retail distribution, branding, and operational & funding capital, giving it a competitive first-mover advantage in rapidly selling proprietary brands focused in the Alcohol, Functional Beverage and Hemp Sectors

(SPONF) Recently Made a Major Announcement regarding one of their Recent Acquisitions as they forge their way into the $25.34BIL Premium Distilled Spirits market and it looks like the players on Wall Street Fell Asleep at the Wheel AND Totally Missed It. (This is Good News for You)


Myles Bartholomew, CEO of SponsorsOne, said: "Since the acquisition of Premier Beverage Consortium, we have developed a portfolio of premium distilled spirits including Bourbon, Vodka, Gin and Whiskey. Working with craft distillers in Texas, we have formulated a lineup of high-quality products that will address the demand of the markets both today and those of the future."

Ron Miranda, CEO & President of Premier Beverage Consortium, stated: "All of our Bourbon's are of a proprietary blend that I have personally blended with the master distiller. This includes our 6-year old Bourbon bottled in bond (BIB) at 100 proof; our 4-year old Bourbon; our Rye Whiskey; and our 4 Grain Whiskey, all bottled at 94 proof."

The Vodka product line will be one of a kind. It has been formulated with a proprietary blend of four different grains to create one of the smoothest and richest tasting vodkas ever introduced to the market.

You Need to Keep Reading to See Why I Am So

Excited About SponsorsOne (SPONF) and it’s Heart-Pounding

Potential for Your Portfolio!

What you need to realize here, is that SPONF Acquired Premier Beverage Consortium late last year, and that Premier Beverage Consortium already lists TWO Major Grocery Chains as their Clients:


...And just You can see why this is such a Big Deal.

Albertsons has 2,252 stores as of the first quarter of fiscal year 2021

And Safeway has over 1,300 stores across the US.

SponsorsOne Inc. (SPONF) has taken huge steps forward recently, placing the Company in an excellent position for rapid growth, all of which indicate the Company's Huge Growth potential!

You see, according to a report produced by Mordor Intelligence the Craft Spirits Market is projected to grow, at a compounded annual growth rate of 18.87% up until at least 2025.

Grand View Research says that the global Craft Spirits Market size is expected to reach USD $80.43B by 2025.

?SponsorsOne Inc. (SPONF) just positioned themselves right in front of an Industry with Tremendous Upside Potential with their recent announcement to develop a portfolio of premium distilled spirits including Bourbon, Vodka, Gin and Whiskey.


The Whisky & Bourbon Market by Itself is Forecasted to

Reach $20.75B by 2025.

The Global Vodka Market is Forecasted to

Reach Over $54B by 2024.


Can we see SponsorsOne Inc. (SPONF) make a Quick and Massive Run back to their 52-Week High and Deliver Potential Gains of +1053.85%?

Big Brands are Starting to Acquire Craft Distillers

Could The Increased Consolidation of Craft Distillers Make

SponsorsOne (SPONF) a "Potential Takeover Target?"

Less than 6 Months ago, market behemoth, Diageo agreed to Acquire Ryan Reynolds Aviation Gin for over $610MIL...


The Company Has Taken Huge Steps Forward Recently,

All Of Which Indicate The Company's Huge Growth Potential

February 9, 2021

SponsorsOne Profiles 4 Corners Vodka

The only Four Grain Vodka on the general market at an everyday price

Myles Bartholomew, CEO of SponsorsOne, said: "4 Corners is an ultra-premium vodka appreciated by every sophisticated Vodka and Bourbon drinker. Texas corn, winter wheat, two-row barley, and Hazlet rye offer the smoothest and cleanest mouthfeel in the vodka category." This is the first Vodka utilizing four grains.

The distillery takes pride in producing a limited volume of an undiluted vodka formula based solely on the purest spirit. Vodka made with the highest quality is only made in small batches. However, our smallest batch is larger than 99% of all distilleries in the country. 5,000-gallon batches guar·antee both quality and consistency under the strictest supervision.

The quality of the water is a significant influence on the character of our Vodka. It's fairly well-known that Texas has extremely pure waters thanks to the limestone bedrock and large aquifers cleaning and purifying.

Production of 4 Corners Vodka will be completed in Q1 2021 and made available to retailers and distributors through Premier Beverage Consortium, SponsorsOne's wholly-owned subsidiary. We expect volume shipments in Q2 2021.

December 15, 2020

SponsorsOne Begins Sample Production Run Of

Doc Wylder's Infused Lemonades

Initial Production Runs Will Be Distributed To National Distributors And Major Retailers For USA, Canada, And Puerto Rico.

First production runs of Doc Wyler's will be configured as six 4-Packs per case, three Packs of Lemonade with vodka, one Pack of Berry infused with vodka, one Pack of Lemonade infused with bourbon and one pack of Lemonade infused with tequila. The ingredients are premium alcohol and real Lemonade, making this one of the first high quality "Ready to Drink" products in the market.

"The buying season for this type of market starts in January to get inventory for the spring break market starting in February," stated Kevin Swadish, President of S1 Brands, a wholly-owned subsidiary of SponsorsOne. Mr. Swadish, who is overseeing product creation, sales and distribution, added: "The making of the Doc Wylder's message is being developed to be different and thought-provoking, tailored to its geographical consumer audience. The marketing will be built to maximize and enhance brand equity. Major retailers have already taste tested all flavors and the response was very favorable, with Vodka, Bourbon and Tequila being the top three categories in the spirits market."

The Doc Wylder's product will be offered in a 4 pack, 8 pack, and 15 pack. The first sample production runs are occurring in the Southern California area. The Company has plans to expand production into multiple locations across the USA and internationally to reduce shipping costs as expansion occurs. The initial samples will be sent to buyers in the Adult Beverage category, including Food/Drug/Liquor and Convenience chains.

Myles Bartholomew, CEO of SponsorsOne, said: "The acquisition Premier

Beverage Consortium with the Doc Wylder's line was to immediately provide the Company a seat at the table in the rapidly emerging RTD's and Hard Seltzer's market that projected to have revenues of te·ns of bil·lion dol·lars through 2025. We are on track to begin full-throttle sales activities by getting these initial production run samples into buyer's hands immediately, which we hope will rapidly enable us to progress towards market launch, revenue, and the reali·zation of pote·ntially significant earn·ings in 2021."

December 2, 2020

SponsorsOne Assembles Management "Dream Team" For Craft Alcohol Product Development, Branding, Marketing, Sales and Distribution

Former COO of Skyy Vodka to Oversee Product Sales & Distribution; Brand Development And Marketing Team Leader's Clients Including Iconic National Brands; And Product Design, Development And Production Leader Developed National Private Label Brands For Trader Joes And Safeway, Restaurant Depo.

Mr. Kevin Swadish, the Former COO Of Skyy Vodka, is to oversee Product Sales & Distribution; Mr. Ricardo Camargo, the Company's Chief Branding Officer, will oversee Brand Development And Marketing -former clients including Adidas, Oakley, Nike, Skullcandy, Timberland, Pepsi, Boost Mobile, Fossil, Crocs, W Hotels, TaylorMade, and Logitech; and Mr. Ron Miranda, who will oversee Product Design, Development and Production, Developed National Private Label Brands For Trader Joes, Safeway And All Their Subsidiaries.

Mr. Kevin Swadish, who has a long and successful track record, leads S1 Brands Inc., a wholly owned subsidiary of SponsorsOne responsible for product creation, sales and distribution. Under Mr. Swadish's leadership subsidiaries will be formed for each major Brand category. In the case of Premier Beverage Consortium LLC ("PBC"), this Company was acquired under S1 Brands and Mr. Swadish's leadership. Our craft alcohol brand development will happen all within PBC.

Mr. Swadish said: "The concept of Doc Wylder's is as developed as any new product I have been involved with. The category, the package and the quality of the beverage itself and our marketing should make this an instant brand. Consumers will try it and keep coming back! The only question I have is which type will be the favorite!"

Mr. Ricardo Carmargo will lead the brand development and marketing team at SponsorsOne Media Inc., a wholly owned subsidiary of SponsorsOne. Mr. Camargo is a nationally recognized leader in Brand creation and building, content generation and influencer marketing.

Mr. Camargo Said: "The Company has assembled this team with some of the brightest minds in technology, sports, music, entertainment and business development to provide industry leadership and market strategy that will spur SponsorsOne's growth and quickly make inroads in the national and international markets."

Mr. Ron Miranda is the founder of Premier Beverage Consortium and now leads the product development and production for craft alcohol within PBC. Mr. Miranda has deep experience in building and launching private label brands for Safeway, Trader Joe's and Restaurant Depot.

Mr. Miranda said: "My mission is to leverage my global supply chain to produce the best quality wine & spirit products at the best price using only the finest and healthiest ingredients available. I feel lucky to work with a team of great, seasoned professionals and with an ever-growing supply of gre·at products to of·fer the public."

Myles Bartholomew, CEO of SponsorsOne, said: "The level and mixture of the talent we have in SponsorsOne will allow us to quickly jump on emerging consumer trends in the Craft Spirits market and get innovative products developed and quickly launched in the market. Brand ideation to full market execution including using our proprietary SponsorsCoin platform for automating the influencer marketing will allow us to get to scale quickly through direct to consumer and wholesale distribution."

November 10, 2020

SponsorsOne Launches Doc Wylder's Line

of Infused Lemonades

Company's first Ready to Drink ("RTD") product line is launched from the acquisition of Premier Beverage Consortium ("PBC") in the RTD market, projected to reach $25BIL by 2025

The new Doc Wylder's product line consists of Lemonades in four types. Lemonade infused with Vodka, Lemonade infused with Tequila, Lemonade and Berry infused with Vodka and a Lemonade infused with Bourbon, all packed in a 12 oz/4pack. The aluminum bottle has a stunning graphic and is recyclable, resealable.

Myles Bartholomew, CEO of SponsorsOne, said: "This product line perfectly fits the current trends of this rapidly expanding category. It is low alcohol, low calorie with no added sugar, and non-GMO. It is also using the most popular spirits for the infusion. Vodka, Tequila, and Bourbon are the largest and fastest-growing segments in the beverage alcohol category. We feel that the product perfectly fits the needs of today's consumer demands and preferences. There is cross over from Beer and Wine Consumers along with the Hard Seltzer consumer. The target is to begin opening national distribution in January and be positioned in stores and other venues starting in the spring. Doc Wylder's will target off-premise distribution in the U.S. and Canada. It is also perfect for on-premise private venues such as golf courses, country clubs, stadiums, recreational locations and other non-retail venues."

November 2, 2020

SponsorsOne To Gain Instant Foothold in The Emerging Craft Spirits And "Ready to Drink" Markets with The Acquisition Of USA Based Premier Beverage Consortium LLC

Craft Spirits Market Is Presently Valued At $46BIL And Ready to Drink Market Is Projected to be $25BIL By 2025; Infused Lemonades, Craft Vodka, and Whiskey are part of the acquired portfolio

This acquisition, which closes November 2, 2020, and made in stock and cash, instantly positions the Company to quickly become a significant player in two rapidly expanding global markets.

The Craft Spirits market is currently valued at $46.7 billion and projected to grow at 25.33% annually forecasted through to 2025, says IndustryARC and Grand View Research, another industry insider projected that the Ready To Drink ("RTD") premixes market size will have revenues of $25.96 billion, also by 2025.

Some of PBC's portfolio of Infused Lemonades, Craft Vodka, and Whiskey/Spirits have gained traction quickly with consumers, propelled by the founding partners' expertise in scaling consumer brands and building brand equity through private labels for Safeway and Trader Joe's.

Myles Bartholomew, CEO of SponsorsOne, said: "This move aligns with Sponsor One's vision to be a bold and innovative, high-end portfolio of distinctive brands and products that deliver exceptional consumer experiences. As part of the agreement, SponsorsOne will work with the Premier Beverage Consortium team to further scale their Brand's growth while leveraging our rich consumer insights and analytics. It will also allow us to apply our brand-building expertise and utilize our high-performing digital technology techniques. Also, our direct to consumer, influencer marketing combined with wholesale distribution will allow us to build and launch brands to meet this demand."

"Our ability to understand and 'empathize' with today's consumer's behavior, wants and needs have been proven through PBC's growth," said Ron Miranda, CEO & President, Premier Beverage Consortium. "We are excited to be working with SponsorsOne, their world-class marketing, and technology team to take our business to the next level and with their leadership team that is making investments in a quickly evolving category."

Bartholomew continued: "Our organizational plan is to roll PBC into S1 Brands Inc, a wholly-owned subsidiary of SponsorsOne, and it will maintain all of its regulatory licenses to sell in 50 USA States and Canada.

September 28, 2020

SponsorsOne Management Announces It Will Be

Applying To Uplist To OTCQB

Company Is Beginning Process To Qualify For OTCQB Venture Market

Myles Bartholomew, CEO of SponsorsOne, said: "We have begun taking steps to meet all the qualifications to up list to the OTCQB Venture Markets, including revamping our company website to make it compliant and more investor friendly. We will also add more information about not just the company, but detailed marketing information on our products and services. This move to a better trading platform should help the company realize increased market value for its existing and future shareholders."

Let’s Summarize and Look at Some Key Highlights

About SponsorsOne (SPONF)

A talent stacked team led by President & CEO Myles Bartholomew, SponsorsOne Inc. (SPONF) is a company that utilizes its proprietary platform that combines digital marketing, wholesale and retail distribution, branding, and operational & funding capital, giving it a competitive first-mover advantage in rapidly selling proprietary brands focused in the Alcohol, Functional Beverage and Hemp Sectors.

SponsorsOne Inc. (SPONF) announced that they have developed a Portfolio of Premium Distilled Spirits including Bourbon, Vodka, Gin and Whiskey on they are on the verge of Disrupting $25BIL Ready to Drink (“RTD”) market with it’s product line launch the Doc Wylder’s line of Infused Lemonades, and their recent Blockbuster News SponsorsOne assembles management “Dream Team” for craft alcohol product development, branding, marketing, sales and distribution, Adding the Former COO of Skyy Vodka to New Management "Dream Team" and plans to Uplist to the OTCQB.

The OTCQB uplisting is a major benefit to (SPONF) because being listed on the OTCQB dramatically increases transparency, reporting standards, management certification and compliance requirements, the majority of broker dealers trade stocks on the OTCQB. Historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.

SponsorsOne Inc. (SPONF) is the leader in the next evolution of digital marketing through influencer marketing, storytelling, and digital-commerce with the SponsorCoin platform and its highly scalable - smart contract-based digital-currency. Combined, this allows brands to build and manage exclusive and highly engaged communities of influencers (from pro to micro-influencers) within the social realm.

According to Forbes, The Amount Spent on Digital Marketing

in 2020 is Expected to Reach $1.3TRL Globally

The SponsorCoin platform provides for data-driven marketing campaigns that will change the way brands connect with their customers.

SponsorCoin is a tool for brands to inspire real movements around their products and services. Their most valuable customers become their best salespeople, producing far higher ROI than current social media advertising methods.

SponsorsOne, through its wholly-owned subsidiary, SponsorsOne Media Inc., provides full creative and Brand building/management services to all our Brands and manages the influencer communities for each Brand.

The influencer marketing industry is on track to be worth up to $15BIL by 2022, up from as much as $8BIL in 2019, according to Business Insider Intelligence estimates.

SponsorsOne Inc. (SPONF) could now have their own brand of Premium Distilled Spirits including Bourbon, Vodka, Gin and Whiskey --Combine this with their in-house Marketing and Influencer Network, and You have a Disruptive Game-Changer.

...No Other Company is Doing This.

If the Brand wants to get big - fast, the wholly-owned subsidiary S1 Brands Inc. will build a wholesale/retail distribution channel for the Brand acting as a master distributor.

S1 Brands provides sales and marketing on behalf of the Brand to its vast network of national wholesalers and retailers and provides purchase order financing to assist the Brand in fulfilling every order.

Ownership of the Brand combined with distribution, digital marketing innovation, and capital is the win·ning formula to build the Win·ning Brand.

Potential Catalyst #1: SponsorsOne (SPONF) Has assembled a Top Management “Dream Team” led by President & CEO Myles Bartholomew, Ron Miranda, President of Premier Beverage Consortium and Mr. Kevin Swadish, the Former COO Of Skyy Vodka.

Potential Catalyst #2: SponsorsOne (SPONF) Recently Made a Major Announcement regarding one of their Recent Acquisitions, Premier Beverage Consortium, as they have developed a portfolio of premium distilled spirits including Bourbon, Vodka, Gin and Whiskey for the forecasted $25.34BIL Craft Spirits Market.

Potential Catalyst #3: SponsorsOne (SPONF) New Acquisition Premier Beverage Consortium late last year, and that Premier Beverage Consortium already lists Two Major Grocery Chains as their Clients: Albertsons with over 2,252 stores and Safeway with over 1,300 stores across the US. (This is Huge Exposure)

Potential Catalyst #4: SponsorsOne (SPONF) Recently launched the Doc Wylder's Line of Infused Lemonades: Company's first Ready to Drink ("RTD") product line is launched from the acquisition of Premier Beverage Consortium in the RTD market, projected to reach $25BIL by 2025.

Potential Catalyst #5: SponsorsOne Inc. (SPONF) With increased Consolidation of Craft Distillers, Could SPONF become a "Potential Takeover Target?" (Sending Shares Soaring). Less than 6 Months ago, market behemoth , Diageo agreed to Acquire Ryan Reynolds Aviation Gin for over $610MIL.

Potential Catalyst #6: SponsorsOne (SPONF) to launch Organic Hemp Cigarette Brand: SponsorsOne to produce an organic hemp pre-rolled cigarette with the goal of delivering up to 15mg of CBD or CBG per cigarette. Hemp Cigarettes - the healthier alternative to Tobacco and Vaping. The total global revenue for tobacco cigarettes is forecasted in 2020 to exceed $711BIL. Hemp cigarettes will compete in this overall market.

Potential Catalyst #7: SponsorsOne (SPONF) Has begun taking steps to meet all the qualifications to up list to the OTCQB Venture Markets, including revamping our company website to make it compliant and more investor friendly. This could be a Huge Catalyst because being listed on the OTCQB dramatically increases transparency, reporting standards, management certification and compliance requirements, the majority of broker dealers trade stocks on the OTCQB. Historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.

Potential Catalyst #8: SponsorsOne (SPONF) A big catalyst (As of this writing) that could potentially send shares breaking out Next Week, is the "Short Interest" in the stock. High Short Interest stocks have been All-the-Rage recently and (SPONF) could be getting ready to potentially “Squeeze the Shorts.” The Short Interest has been slowly creeping up again on (SPONF) but this time we caught them. This could send shares of (SPONF) Soaring to new levels if a Short Squeeze ensues.

Potential Catalyst #9: SponsorsOne (SPONF) Wall Streets leading provider of market data to the global financial, media, and commodity industries Barchart.com just Triggered an "ASTOUNDING" 11 BUY SIGNALS across the Short-Term Indicators, Medium-Term Indicators and even the Long-Term Indicators.

?A big catalyst that could potentially send shares breaking out higher is Wall Street’s leading provider of market data Barchart, which upgraded (SPONF) to a 100% BUY rating short-term.

I strongly suggest read the technicals to learn why SPONF could be potentially indicating that a Bigger Breakout is Imminent.


StockTA Technical Opinion Rating Issued

SPONF "Very Bullish"

Additionally, another catalyst that points to a potential breakout is respected technical analysis site StockTA. Their technical indicators triggered SPONF "Very Bullish."


SPONF Looks Poised For Potential "Short Squeeze" Which Could

Send Shares Soaring +500% in Upside Potential?

With so many major developments in the pipeline for (SPONF), from their newest product line launch in the $25BIL "RTD" market, combined with their latest news they’re making an ultra-premium vodka, and as their new Management "Dream Team" and UPLISTING news spreads a potential Breakout could be IMMINENT!

This could be the chance to take advantage of a company which is exhibiting strong growth potential, extreme diversity, and a highly-favorable technical setup!

SPONF just pulled back to an Attractive Price and Could be setting up for its Next Potential Major Breakout to the Upside, and if this "Short Squeeze Happens" there is No-Telling what could happen.

Huge Breakout Setup For SPONF

SPONF RSI (Relative Strength Index) is hovering around 58 and could be potentially indicating that a Bigger Breakout is Imminent.

If SPONF’s RSI Crosses Over the 60 or 70 Level

There is No-Telling What Could Happen

Below you can see a screenshot of a chart, which shows SPONF's RSI crossed over the 60 and 70 Level when I alerted it in January. In fact, I alerted it on Jan. 19th and it opened at $.0088 and it rocketed to a high of $.0318 when I alerted it on Jan. 26th for Potential Gains of +261.36%.

Once again, SPONF's RSI (Relative Strength Index) is hovering around 58 and could be potentially indicating that a Bigger Breakout is Imminent. (Could be setting up for another Huge Run?)


If SPONF’s RSI Crosses Over the 60 or 70 Level

There is No-Telling What Could Happen

Once again, (SPONF) just pulled back to an Attractive Price and Could be setting up for its Next Potential Major Breakout to the Upside, and if this "Short Squeeze Happens" there is No-Telling what could happen.

As I was doing my research I observed a simple pattern which could be potentially indicating that a Massive Short Squeeze is about to send shares of (SPONF) Potentially Soaring…

If you look at the screenshot at the top of this report, you will see on Wed. Feb. 10th, the Short Volume on (SPONF) was 68.09% of the total session volume. This is the same setup we saw last month when on Jan. 19th, I alerted (SPONF) at $.0088 and it ran to $.0318 on Jan. 26th for Potential Gains of +261.36%

?You need to have (SPONF) up on your screen (First Thing) this morning!

I am urging all of our members to add (SPONF) to the top of your watch list right now, and be ready this morning at the opening bell!

Sincerely,

Editor In Chief, OTCtipReporter Team

[VApopeye]

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment https://ir.aikidopharma.com/news-releases/?qmodStoryID=6836425476481955

[billionsmatter]

It's on the move pre-market. Amy predictions? 1.6200 +0.14 (8.11%)
Before hours: 8:52

[Taurus69]

$aiki $1.49 v -0.04 (-2.61%)
Volume: 3,753,532 @02/05/21 7:59:49 PM EST

[3antar]

$AIKI great setup, maybe a great cancer Therapeutics for men and great therapy for your portfolio

[billionsmatter]

News out today: AIkido Pharma Adds Inventor Dr. Neil H. Bander, M.D. to Scientific Advisory Board

New Board Member Brings Expertise in Oncology Research

NEW YORK, Feb. 2, 2021 /PRNewswire/ -- [url]AIkido Pharma Inc (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Neil H. Bander, M.D., a physician-researcher at Weill Cornell Medicine, has joined the Company's Scientific Advisory Board.

"Dr. Bander heads one of the world's most experienced and accomplished teams in antibody-targeted therapy of prostate cancer at Cornell University and is a widely respected inventor of patented technologies and recognized expert in the field of urological oncology," commented Mr. Anthony Hayes, CEO of AIkido. "Importantly, Dr. Bander is the inventor of targeted radiopharmaceutical therapy technology at Convergent Therapeutics, Inc. which we are proud to support. We are honored to have him join our team of advisors and work more directly in our efforts to advance the development of this technology."

"Using his clinical background and laboratory efforts, Dr. Bander has exemplified the role of surgeon-scientist," added Mr. Hayes. "His research has spawned novel clinical trials that are unique in urological oncology and have already made a difference in the lives of prostate cancer patients. We look forward to leveraging his expertise as we continue to develop our platforms and forge a path towards the treatment of cancer."

Dr. Bander, M.D. completed fellowship training in both tumor immunology and urological oncology at Memorial Sloan-Kettering Cancer Center in New York City. Subsequently, at New York-Presbyterian Hospital-Weill Cornell Medical Center (NYPH/WCM), where he is the Bernard and Josephine Chaus Professor of Urologic Oncology, he has focused on clinical urological oncology and the development of monoclonal antibodies for targeted cancer therapy. As a result of his efforts, his research group developed the first antibodies to prostate-specific membrane antigen (PSMA) that could effectively bind prostate cancer cells. As a result of his efforts, PSMA is now recognized as the most prostate-cancer specific cell surface antigen known and is the target of a wide variety of anti-cancer technologies. The NYPH/WCM Uro-Oncology research team has sponsored more than 15 clinical trials with anti-PSMA antibodies and more recently, small molecule PSMA agents, in prostate cancer patients with more than 500 patients treated in these trials.

Dr. Bander said, "I look forward to joining my Weill-Cornell colleague, Dr. Scott Tagawa, on AIkido's SAB, as well as the other AIkido team members, to generate advances that make an impactful difference in the lives of cancer patients."

About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: [phone]
Email: [e-mail]
www.haydenir.com

AIkido Pharma Inc.:
Phone: [phone]
Email: [e-mail]
www.aikidopharma.com

Cision
Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-adds-inventor-dr-neil-h-bander-md-to-scientific-advisory-board-301220019.html

SOURCE AIkido Pharma Inc.

Originally published Tue, February 2, 2021, 8:00 AM

[billionsmatter]

AIkido Pharma Setting Up to Be Major Player in

The Booming $176BIL Anti-Cancer Therapeutics Sector

With Their Latest Blockbuster News!

Dear Fellow Trader,

Immediately turn your attention to AIkido Pharma Inc. (AIKI)

AIkido Pharma Is An Artificial Intelligence-Cancer Fighting-Biotech

Company Like You’ve Never Seen Before.

The Company has several bullish catalysts in the pipeline, and is on the verge of disrupting a $176BIL Anti-Cancer Therapeutics Market, with latest Blockbuster News AIKI secures early investment in Next Generation Radiotherapy Company Convergent Therapeutics currently in Human Phase 2 Trials for Treatment of Prostate Cancer.

This acquisition, instantly positions AIkido Pharma as a significant player in rapidly expanding $176 Billion Anti-Cancer Therapeutics Market!

Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. and foreign patents.

Convergent is currently conducting advanced human trials relating to prostate cancer treatments involving peptide receptor radionuclide therapy ("PRRT") that targets the prostate-specific membrane antigen ("PSMA") present on prostate cancer cells.

The technology was developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.

The key component of Convergent's PRRT prostate cancer therapy is its proprietary drug, CONV 01-a, a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter.

The function of CONV 01-a is unique in that it not only binds specifically to the PSMA receptor on prostate cancer cells, but also stimulates the internalization of the receptor along with itself and its powerful radioactive payload directly into tumor cells.

Convergent is presently conducting two sets of human clinical trials using CONV 01-a as a single agent treatment for prostate cancer.

The first is a Phase 1a/2a Single Ascending Dose Trial of CONV 01-a and the results are expected to be released in Q2 2021.

In August of 2020, Convergent began a second Phase 1b/2a trial to test the efficacy of multiple ascending doses of CONV 01-a.

If FDA approved, CONV 01-a would be the first antibody drug approved to direct a radioisotope into prostate cancer cells, and the first drug approved for the use of 225Ac in cancer treatment.

Another company is currently studying PSMA I&T-ß, containing 177Lu, and has just completed a phase 3 trial in prostate cancer. Separately, Novartis (NYSE: NVS) is pursuing FDA approval for another 177Lu-small molecule drug for prostate cancer treatment, designated 177Lu-PSMA-617, which also binds PSMA. Novartis has recently completed a phase 3 registration trial for treatment of metastatic castration-resistant prostate cancer (mCRPC), a form of advanced prostate cancer. Like PSMA I&T-ß, Novartis's 177Lu-PSMA-617 may also be a promising candidate for use with CONV 01-a in the proprietary dual PRRT therapy.

Aikido's CEO, stated, "This is by far the most advanced technology in which the Company has participated. The first of the human trials is wrapping up, with data to be reported shortly, and with the remaining trials either underway or scheduled to begin imminently. Participation in this advanced work represents a major and potentially transformative step for the Company and we are honored to be a part of it. I optimistically anticipate the first of the results to be released next quarter. We will update our shareholders as soon as the data is released."

AIkido Pharma Setting Up To Be A Major Player In The $176 Billion

Anti-Cancer Therapeutics Market That Is Exploding Exponentially!

Another Catalyst Is Convergent Therapeutics Experienced

First in Class Operational Team.

The operational team are some of the brightest people in the world!

Once you wrap your head around who the operational team and founder is, I can assure you that you too will see we could potentially have another big breakout gainer on our hands.

Philip Kantoff, MD CEO - Convergent Therapeutics

Memorial Sloan Kettering Cancer Center (MSK)

Chairman, Department of Medicine, 2015-present
Grew faculty at MSK’s Department of Medicine by >200 (currently ~484 total) through recruitment of national and international clinical and research leaders in oncology
Increased the annual research funding of the Department of Medicine to over $300 million dollars. An increase of 78% since starting in 2015
Created and pushed forward research programs that have produced dozens of cancer related FDA drug approvals
Steered the department through the COVID-19 crisis
Neil Bander, MD CSO / Founder - Convergent Therapeutics

Weill Cornell Medicine

Bernard and Josephine Chaus Professor of Urological Oncology and Director of Urological Oncology Research at Weill Cornell Medicine
His team has the world’s largest experience in antibody discovery and clinical development in urological oncology.
Developed the first monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could successfully target prostate cancers in patients.
Pioneered the clinical validation of PSMA and PSMA-Targeted Therapeutics (Radionuclides and Antibody-Drug Conjugates).
John Cullity, MD MBA CFO / CBO

Managing Director at BioSynergy Partners, a life science advisory spun out of Torreya New York where he was CBO.
Provides strategic advisory on M&A, partnering and financing to life-science companies worldwide.
Chairman Race Oncology (RAC.ASX). Director of several life sciences start-ups.
Oncology BD team leader and Head of Strategic Pricing at Sanofi, Health Economist at Schering Plough, Consultant at A.T. Kearney.
Board certified internist: Royal College of Physicians, UK. Wharton MBA.
Upgraded Bullish - FDCT is Off to A Strong Start!

Are You Watching? Looking Very Strong as Volume Surges!

So far, FDCT is breaking out to the upside fast hitting a high of $.57 yesterday up 23% from previous sessions close.

There has been a massive shift into Bitcoin and Cryptocurrency, prices have climbed after stock trading app Robinhood stepped in to restrict users from GameStop and other stocks that have surged in recent days.

We are in the midst of another Crypto Frenzy and companies like FDCT have the potential to make serious moves this week.

If you haven't taken a look at this stock yet, this is your chance. Make sure you have FDCT pulled up on your trading screen.

Sincerely,

Editor In Chief, OTCtipReporter Team

[billionsmatter]

Have you checked out Convergent Therapeutics, Inc? It's a startup pharmaceutical company that is focused on developing next generation radiopharmaceutical therapy for prostate cancer and other applications. Its proprietary technology involves peptide receptor radionuclide therapy (“PRRT”) developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine. With them teaming up with AIKI this is something to look at.

[Finditdotcom]

News Out AIKI: Aikido Pharma Secures Early Interest in Next Generation Radiotherapy

Currently in Human Phase 2 Trials for Treatment of Prostate Cancer
New York 2/1/2021 8:00:00 AM
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company executed a Two Million Dollar Convertible Promissory Note Purchase Agreement with Convergent Therapeutics, Inc., securing an early investment in Convergent. Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. and foreign patents.


https://www.findit.com/aikido-pharma/news/1813161/aikido-pharma-secures-early-interest-in-next-generation-radiotherapy

[georgie18]

AIKI...$1.70...in the P/M...NEW YORK, Feb. 1, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company executed a Two Million Dollar Convertible Promissory Note Purchase Agreement with Convergent Therapeutics, Inc., securing an early investment in Convergent. Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. and foreign patents.

Convergent is currently conducting advanced human trials relating to prostate cancer treatments involving peptide receptor radionuclide therapy ("PRRT") that targets the prostate-specific membrane antigen ("PSMA") present on prostate cancer cells. The technology was developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine...:party:

[mick]

https://otcbb.swingtradebot.com/equities/AIKI

N.Y. , NASDAQ
https://swingtradebot.com/equities/AIKI

[ClayTrader]

* * $AIKI Video Chart 01-26-2021 * *

Link to Video - click here to watch the technical chart video

[billionsmatter]

Profit Alert: AIKI Rockets From Alert of $.84 to Staggering $2.15 TODAY

Running Up +155.95% (More Huge Profits) What Did I Tell YOU...

Profit Alert: GWHP Rockets From Alert of $.49 to Staggering $2.12 TODAY

Running Up +332.65% (More Huge Profits) What Did I Tell YOU...

Profit Alert: SPONF Rockets From Alert of $.009 to Staggering $.0318 TODAY

Running Up +253.33% (More Huge Profits) What Did I Tell YOU...

Another Incredible Day for My Alerts...

What did I tell you?

Congrats, SPONF rocketed to a staggering high of $.0318 today running up +253.33% from my alert price on Jan 19th of $.009/share.

Also, one of my previous picks AIKI which I alerted you on Jan 6th and it started trading premarket at approx. $.84 and rocketed to an intraday high of $1.75, providing members with +108.33% gains from my premarket alert at $.84/share. today it Rocketed to a high of $2.15 up +155.95% from alert price.

I alerted you my #1 Covid-19 Diagnostics stock GWHP on Jan 12th at $.49/share, today it Rocketed to a high of $2.12 providing members with +332.65% gains.

I told you I was going to be sending you a lot of explosive picks this month that have the potential to move big and to move FAST!

For anyone that may have missed my email from earlier, I've included a copy of my alert below:

Breaking News Hits Wire! SILO Announces Reaches Terms with

University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease



Dear Fellow Trader,



Immediately turn your attention to Silo Pharma Inc. (SILO)



SILO just released news today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.



News Link Here - snapshot below



JANUARY 26, 2021



Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease



Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.



The exercise of the option agreement allows for Silo to negotiate an exclusive patent license agreement. The option agreement included pre-negotiated business terms for the exclusive patent license, which we expect to finalize shortly.

Mr. Eric Weisblum, Chairman and CEO of Silo Pharma, commented, “Silo is pleased to advance our research collaboration with UMB in the fight against Neuroinflammatory diseases. We are focused on the development of this novel therapeutic targeting those who have been afflicted with CNS inflammatory diseases. Management looks forward to sharing the preclinical results of this Novel Homing Peptide upon completion of our initial study in connection with UMB."

-----------------------------------------------------------------------------------------------------

This could be the beginning of a Massive Short Squeeze and has the Potential to Send Shares Soaring Much Much Higher.



As you know, a “Short Squeeze” is a Stock Market Phenom that can send shares of a stock Dramatically Higher in a short period of time—generally anywhere from a few hours to a few days. Any stock is susceptible to a short squeeze, but those with low volume are especially vulnerable.



...Now take a look at the Short Report on SILO:


Last Thursday, 60.34% of the volume was Short… then on Friday an astounding 65.12% of SILO’s volume was Short... Then yesterday 61.29% of the volume was Short.



These Shorts will have to cover and this could potentially cause a Short Squeeze and send shares of SILO Soaring…



You do not want to miss out on SILO… especially if we see signs of a Short Squeeze about to Send Shares Soaring.



If you haven't taken a look at this stock yet, this is your chance. Make sure you have SILO pulled up on your trading screen.

Regards,

Your PPF Team

[billionsmatter]

Profit Alert: SPONF Rockets From Alert of $.009 to Staggering $.0318 TODAY

Running Up +253.33% (More Huge Profits) What Did I Tell YOU...

Another Incredible Day for My Alerts...

What did I tell you?

Congrats, SPONF rocketed to a staggering high of $.0318 today running up +253.33% from my alert price on Jan 19th of $.009/share.

I alerted you my #1 Covid-19 Diagnostics stock GWHP on Jan 12th at $.49/share, today it Rocketed to a high of $2.12 providing members with +332.65% gains.

Also, one of my previous picks AIKI which I alerted you on Jan 6th and it started trading premarket at approx. $.84 and rocketed to an intraday high of $1..94, providing members with +108.33% gains from my premarket alert at $.84/share... Today it Rocketed to a premarket high of $1.66 up +97.61% from alert price.

I told you I was going to be sending you a lot of explosive picks this month that have the potential to move big and to move FAST!

For anyone that may have missed my email from earlier, I've included a copy of my alert below:

Breaking News Hits Wire! SILO Announces Reaches Terms with

University of Maryland Baltimore for Exclusive License of Central Nervous

Homing Peptide for Neuroinflammatory Disease

Dear Fellow Trader,

Immediately turn your attention to Silo Pharma Inc. (SILO)

SILO just released news today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.

News Link Here - snapshot below

JANUARY 26, 2021

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.

The exercise of the option agreement allows for Silo to negotiate an exclusive patent license agreement. The option agreement included pre-negotiated business terms for the exclusive patent license, which we expect to finalize shortly.

Mr. Eric Weisblum, Chairman and CEO of Silo Pharma, commented, “Silo is pleased to advance our research collaboration with UMB in the fight against Neuroinflammatory diseases. We are focused on the development of this novel therapeutic targeting those who have been afflicted with CNS inflammatory diseases. Management looks forward to sharing the preclinical results of this Novel Homing Peptide upon completion of our initial study in connection with UMB."

If you haven't yet read SILO full profile, do so HERE

Click here to get the full Report!



This could be the beginning of a Massive Short Squeeze and has the Potential to Send Shares Soaring Much Much Higher.

As you know, a “Short Squeeze” is a Stock Market Phenom that can send shares of a stock Dramatically Higher in a short period of time—generally anywhere from a few hours to a few days. Any stock is susceptible to a short squeeze, but those with low volume are especially vulnerable.

...Now take a look at the Short Report on SILO:


Last Thursday, 60.34% of the volume was Short… then on Friday an astounding 65.12% of SILO’s volume was Short... Then yesterday 61.29% of the volume was Short.

These Shorts will have to cover and this could potentially cause a Short Squeeze and send shares of SILO Soaring…

You do not want to miss out on SILO… especially if we see signs of a Short Squeeze about to Send Shares Soaring.

If you haven't taken a look at this stock yet, this is your chance. Make sure you have SILO pulled up on your trading screen.

Sincerely,

Editor In Chief, OTCtipReporter Team

[Jimmy99er]

I'm thinking 2.00 at least

[billionsmatter]

They recently covered AIKI FDIT AND GWHP COMPANY: Silo Pharma Inc.

SYMBOL: SILO

ALERT RANGE: $.35 - $.37

Dear Fellow Trader,

First things first, I’d like to extend a “Huge Welcome” to all of our New Members and for our loyal ones, a big Congrats on our recent big picks!

We are coming off recent gainers like my previous pick Aikido Pharma (AIKI) which ran up +108.33%. I alerted AIKI on Jan 6th and it started trading premarket at approx. $.84 and rocketed to an intraday high of $1.75, providing members with +108.33% gains from my premarket alert at $.84/share.

Earlier last week, I alerted you my Covid-19 Diagnostics stock Global WholeHealth Partners (GWHP) at $.49 and rocketed to a high of $2.17 Showing Off Potential Gains of +342.85%.

Then I Alerted you on Cannabis Suisse Corp. (CSUI) and it broke out to the upside fast hitting a high today of $.149/share up +62.30% from Thursday’s intraday low of $.0918.

If you liked your previous picks above that I just mentioned, I believe you are going to love your NEXT New Breakout Stock for Monday... SILO

Turn Your Complete Attention to SILO

Monday's Focus Stock

Immediately turn your attention to Silo Pharma Inc. (SILO)

?Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research based out of New Jersey. Not many people know this but New Jersey is the Global Leader when it comes to Pharmaceutical and Biotechnology Industries.

Keep Reading to See Why You Need to Pull Up

Silo Pharma Inc. (SILO) Right Now


Many Psychedelic Stocks Just Experienced Triple-digit

Returns - as much as +799%, +471%, and +302%

Silo Pharma Inc. (SILO) Could be Getting Ready to Take Off

Silo Pharma Inc. states their mission is to identify assets to license and fund the research which they believe will be transformative to the well-being of patients and the healthcare industry.

In these uncertain times, the mental health of the nation and beyond is being put to the test. More than ever, creative new therapies and lines of thought are needed to address health challenges of today. Combining their resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

If we look at the chart pattern on any of the leading psychedelic stocks, we should see a nice series of higher highs and higher lows. The reason for this increased interest in Psychedelics is improved mental health.

More than 264M people worldwide suffer from depression and mental health disorders are on the rise in every country in the world. Mental health is something every one of us should be talking about. Since serotonin and norepinephrine reuptake inhibitors came to market in the 1980s and 1990s, we have not seen a lot of life changing new pharmacological therapies for mood disorders until the FDA approved esketamine in March 2019.

Silo’s goal is to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.

Silo Pharma Inc’s management and founders have played key

roles in numerous successful biotech companies.

Silo Pharma Inc. (SILO) is well-capitalized with access to additional funds as oppor·tunities present themselves.

Silo Pharma Inc’s CEO and Founder, Eric Weisblum, has over 25 years of Wall street experience most recently in the biotechnology sector. Eric served on the board of directors of Aikido Pharma, a Nasdaq-listed biotech company focused on the commercialization of oncology therapeutics where he advised on the operations and licensing of their technology. Prior to Aikido, he was the President of Sableridge Capital.

POTENTIAL CATALYST THAT COULD SEND SHARES

OF SILO PHARMA (SILO) SOARING NEXT WEEK

Potential Catalyst #1: Silo Pharma Receives $1 Million in Up Front Patent Licensing Deal for its Psilocybin Cancer Therapeutic Applications: The license agreement (the “Agreement”) with Aikido Pharma Inc. (Nasdaq: AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop Therapeutics for the treatment and complications of Cancer. (This Could be Huge)

Potential Catalyst #2: Investor Interest In This Space is Sending Psychedelic Stocks Soaring To Incredible New Heights. Many Psychedelic Stocks Just Experienced Triple-digit Returns- as much as +799%, +471%, and +302%

Potential Catalyst #3: One of the Strongest and Talented Management Teams that I have seen in the Psychedelic Space. SILO has direct ties to Johns Hopkins which is one of the leading Universities in the Psychedelic Space. (This Could be Huge)

Potential Catalyst #4: Silo Pharma announced Blockbuster News they're to explore unique peptide delivery of psilocybin utilizing this novel technology represents key differentiator in emerging psilocybin space. Silo Pharma announced that it has executed an option agreement with the University of Maryland, Baltimore with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology.

Silo Pharma’s intends to explore the development of unique therapeutics that utilize these CNS Homing Peptides. Silo plans on initiating studies to evaluate the potential use of this invention to deliver Psilocybin based therapeutics directly to targeted areas of a patient.

This technology refers to phage-encoded peptides identified as being unique, inflamed CNS-specific markers. These peptides zero in on the spinal cord and, to a lesser extent, the cerebellum, in a rodent model of Multiple Sclerosis (MS).

These peptides are designed to address many challenges, as they are expected to be pathology-specific (damaged, inflamed tissue only), are tissue specific (CNS), and can be used as an imaging tool for inflammation of the spinal cord. As such, Silo Pharma believes that they may be used in the detection of diseased tissue and for targeting therapeutic agents to the CNS to treat MS and other neuroinflammatory diseases.

Potential Catalyst #5: Silo Pharma Launches Scientific Advisory Board with Appointment of a Physician of John Hopkins University: “Psilocybin research is one of the most intriguing and fastest growing areas of biotechnology, as it is believed that psychedelics hold the potential to address some of the largest and most challenging diseases such as depression, CNS related disorders, anxiety, PTSD, and Parkinson’s,” said Eric Weisblum, CEO of Silo Pharma. “The establishment of our Scientific Advisory Board reflects our commitment to pursuing multiple, strategic opportunities for privately-funded research. An advisory board of expert researchers will be instrumental in guiding us through the process of selecting and funding the best opportunities for the advancement of our mission and to maximize returns.”

Working with psychedelics since 2004, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He is the Principle Investigator on research showing promising data for psilocybin in treating tobacco addictions, and on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD. In 2016, Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress.

“Matt has long been recognized for his behavioral research in psychedelics and pharmacology,” added Weisblum. “His experience and talents will be invaluable as we accelerate our pursuit for the application of psychedelic drug therapies. We welcome Matt to our advisory board and look forward to leveraging his insights and expertise.”

Dr. Johnson was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association and is current President of the International Society for Research on Psychedelics, an organization he founded with colleagues. He has received continuous NIH funding as Principal Investigator since 2009. He has reviewed for more than 75 journals and has served as guest editor on two special issues on psychedelics.

Dr. Johnson has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the US. He is a standing member of the Addictions Risks and Mechanisms (ARM) NIH study section. He has provided invited presentations in 13 nations.

Bottom line, SILO could turn out to be another potential double-digit breakout gainer like my previous win·ners.



So, without wasting any more time, don't delay and pull up SILO on your trading screen for Monday before you miss out on another huge potential win·ner, with tremendous upside potential.

...And if you remember, I recently Alerted on Aikido Pharma (AIKI) at $.84 and rocketed to an intraday high of $1.75 -- Showing Off Potential Gains of +108.33% within a 24-Hour period.

Earlier last week, I alerted you my Covid-19 Diagnostics stock Global WholeHealth Partners (GWHP) at $.49 and rocketed to a high of $2.17 Showing Off Potential Gains of +342.85%.

Then I Alerted you on Cannabis Suisse Corp. (CSUI) and it broke out to the upside fast hitting a high today of $.149/share up +62.30% from Thursday’s intraday low of $.0918.

Could Silo Pharma Inc. (SILO) be my next Massive Win·ner?

Investor Interest In This Space is Sending Psychedelic Stocks Soaring To Incredible New Heights.

Let’s Take a Closer Look At Silo Pharma Inc. (SILO) and why I think they are Ready for a Potential Massive Breakout to the Upside.

Silo Pharma Inc. (SILO) Growth Plans:

- Identify and target assets to license

- Partner with world-class medical research organizations

- Research and study indications

- Target FDA designations: Break Through Therapy, Orphan & Fast Track

- Big pharma partnerships

Silo Pharma Inc. (SILO) Psychedelics Opportunity:

- Build out industry leading scientific advisory board

- Combine generics with Psilocybin, MDMA, LSD

- Build Intellectual Property through research and innovation

- Targeting Mental health and rare neurological diseases

Last week, even The UFC Announced it was “Diving into” Psychedelics

UFC looks into Johns Hopkins study on psychedelic drugs as potential therapy for fighters

The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health.

The promotion has been in contact with Johns Hopkins University about its psychedelic studies with an eye toward seeing if the drugs can be helpful for fighters dealing with brain issues, UFC president Dana White told MMA Junkie on Wednesday.

"We're diving into that," Dana White said.

UFC senior vice president of health and performance Jeff Novitzky told ESPN that the interest came from a segment from HBO's "Real Sports" last month. Novitzky said White gave him a "directive" to look more into psychedelic research and he has been in contact with Johns Hopkins over the past few weeks.

The UFC has been a key funder of a professional athlete brain study being conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health, contributing another $1 million last week. Novitzky said the promotion could look to be a benefactor toward a psychedelic study with the added possibility of recruiting current or former UFC fighters to be part of the research.

"Dana said, 'Hey, find out what this is about,'" Novitzky said. "To see if it does help with some traumatic brain injury, addiction, mental-health problems. We want to be on board and we want to be first."

Johns Hopkins is the nation's leader in research on the therapeutic effects of psychedelics such as psilocybin (mushrooms) and LSD. The Johns Hopkins Center for Psychedelic & Consciousness Research gained regulatory approval from the U.S. government in 2000 and has produced more than 60 pieces of peer-reviewed research.

Currently, psilocybin and other psychedelics are classified by the U.S. government as illegal Schedule I drugs, defined as drugs with a high potential for abuse or drugs that have no medical uses.

However, views on psychedelics are changing. Oregon lega·lized psilocybin in a vote last year.

"Our research has demonstrated therapeutic effects in people who suffer a range of challenging conditions including addiction (smoking, alcohol, other drugs of abuse), existential distress caused by life-threatening disease, and treatment-resistant depression," states the Johns Hopkins Center for Psychedelic & Consciousness Research website.

Former UFC flyweight contender Ian McCall has been working with psilocybin and athletes and has taken part in a study with Johns Hopkins, he told ESPN's Michael Rothstein last year. McCall said he has already had discussions with the UFC.

"When you go into a cage, when you go into a ring and you fight and even football, you're giving and receiving [post-traumatic stress syndrome] and no one wants to talk about it, but that's what's happening," McCall said. "Your trauma is stored in your tissue, so you're actually giving and receiving PTSD while you're in there and that's a big reason why I work in psychedelics, to try and fix those exact things. We need to take care of these athletes a little better, just like we need to do with vets."

Novitzky said he has spoken to athletes who have experimented with psychedelics such as ayahuasca, and those who have struggled with addiction or mental health have said the drug has been extremely helpful. The UFC exec said he's not sure on a timeframe on when the promotion could do something in the psychedelic field, but that the desire is there.

"We want to do it the right way," Novitzky said. "We want to get all the government approvals if we're going to do something. We want to figure out how we're going to recruit fighters. Unfortunately, it's not something that happens overnight. But Dana has basically instructed me: 'Hey I want this looked into. Bring me some potential avenues we can be involved.'"

White said, like with the UFC's participation in the brain health study, there is a desire to look more into potential therapies for fighters with brain issues. UFC veteran Spencer Fisher opened up about his health problems, including lesions on his brain, in an interview with MMAFighting.com that was published Tuesday.

"He's not the first and he's definitely not gonna be the last," White said of Fisher. "This is a contact sport. Anyone has ever done this [when they were] younger -- myself included -- is dealing with brain issues. It's part of the gig."

SILO PHARMA RECENT NEWS :

JANUARY 19, 2021

Silo Pharma to Participate in Virtual Conference

on Investing in Psychedelics

NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, today announced that Founder and CEO Eric Weisblum will participate in the “Investing in Psychedelics Series: Building Value Through IP” virtual conference hosted by The Canadian Securities Exchange (CSE), CFN Media Group (OTCQB: CNFN) and Zuber Lawler on Wednesday, January 20, 2021. The live panel discussion is scheduled to begin at 1 PM EST. and will be followed by a Q&A session.

JANUARY 13, 2021

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous System

Englewood Cliffs, NJ, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, today announced that it has entered into a sponsored research agreement with the University of Maryland, Baltimore relating to a study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis.

According to the National Multiple Sclerosis Society, an estimated 1 million people live with MS in the United States. Silo Pharma is seeking to develop treatments, including the use of targeted drug delivery to the Central Nervous System (CNS) as a means of overcoming many of the limitations of current therapies. The study will seek to identify the various cell types that are responsive to a series of peptides to understand how drug-carrying liposomes ultimately interact with the CNS tissue cells.

“We are to be collaborating with researchers at the University to begin a study of this novel peptide-guided drug delivery approach for the treatment of multiple sclerosis. This study is an important step in gathering research and data to treat rare neurologic diseases with the CNS peptide,” stated Eric Weisblum, Chairman and CEO of Silo Pharma. “We believe that, when combined with the findings of our previously announced investigator-sponsored study, which utilizes repeated low doses of LSD and Psilocybin effects on cognitive and emotional dysfunction in Parkinson's disease and to understand its mechanism of action, we will gain valuable data needed to analyze the potential of these peptides to be used in combination with psilocybin, LSD, or traditional drugs, as potential therapeutic agents.”

JANUARY 11, 2021

Silo Pharma Provides Details of Patent License Agreement

for Psilocybin and Cancer Applications

Silo Pharma to Receive Upfront Payment Combination of Cash and Preferred Stock Totaling $1MIL

Englewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million. The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop therapeutics for the treatment and complications of cancer.

In consideration for granting the license, Silo Pharma received a one-time cash payment of $500K and shares of newly designated Convertible Preferred Stock valued at $500K on the date of execution of the license. Silo Pharma will also be entitled to potential royalty payments on Net Sales (as defined in the Agreement) in the event that the licensed property is commercially developed.

“Our Agreement advances Silo Pharma’s unique approach to researching and discovering therapeutics that can be used in combination with psychedelic elements” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are enthusiastic about this agreement and opportunity. Researching the use of psilocybin to treat both cancer and cancer side effects is a noteworthy opportunity for Silo Pharma and its shareholders. We look forward to updating investors on this agreement and further developments.”

Further information regarding the Agreement can be found in the Company’s Form 8-K filed with the SEC on January 11, 2021.

JANUARY 6, 2021

Silo Pharma Inc. Receives $1M Dollars in UpFront Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma’s patent application relates to using a novel peptide with Psilocybin as a therapeutic.

Eric Weisblum, CEO of Silo Pharma, Inc, stated “We are excited about this opportunity as we continue to execute our plan to bring novel therapeutics to patients inflicted with neurological disorders and rare diseases, which we hope will bring about breakthroughs that can lead to improved care. This agreement is structured to provide $500K in an upfront cash payment as well as equity currently valued at $500K from a NASDAQ listed company. The Agreement also provides for Silo to collect royalties should the technology be commercialized.”

Now Let’s Take a Closer Look The Ama·zing Management Team Behind Silo Pharma Inc. (SILO)

Eric Weisblum - CEO

Eric Weisblum is the founder and Chief Executive Officer of Silo Pharma Inc. Prior to Silo Pharma Mr. Weisblum was a private investor and advisor to several of his portfolio companies. Mr. Weisblum has experience in both inlicensing therapeutic assets and assisting in their development. As a result, Mr. Weisblum brings with him nearly 20 years of experience in structuring and trading financial instruments. Mr. Weisblum is involved in his community and can often be found on the soccer field with his family of four. He holds a B.A. from the University of Hartford’s Barney School of Business.

Kevin Muñoz - Board Member

Dr. Kevin Muñoz, 43, was appointed to the Board of Directors on October 1, 2020. Dr. Muñoz currently serves as Director of Operations at Physical Medicine and Rehabilitation where he has responsibility for the day-to-day management of all office operations with a focus on ensuring and increasing patient satisfaction. Prior to that, he led the configuration efforts during an enterprise-wide implementation of application software that also included streamlining and improving business processes. Kevin began his career with Harlem Health Promotion Center in New York City as a Research Assistant where he was responsible for data collection and interpretation. Dr. Muñoz earned a Bachelor of Science from the University of Michigan where he graduated with distinction and a Doctor of Medicine from Xavier University School of Medicine, Aruba NA.

Wayne Linsley - Board Member

Wayne D. Linsley, 64, has served as a director of the Company since January 2020. Mr. Linsley has been in business management for over 40 years. He possesses a wide and varied skill set including sales and sales management, finance (for both public and private companies), accounting, audit support and financial reporting. He has a bachelor’s in business administration from Siena College in Loudonville, NY.

Since 2009 he has worked for and is currently a Vice President for CFO Oncall, Inc., a financial reporting firm that works with publicly traded companies. He has extensive knowledge of financial statements, MD&A, SEC Filings (10K, 10Q, 8K, etc.) Edgar, etc. He often negotiates on behalf of clients in such areas as audit fees, transfer agents, Edgar companies, etc.

Matthew W. Johnson, Ph.D. - Scientific Advisor

Matthew W. Johnson, Ph.D., Professor at Johns Hopkins, is an expert on psychedelics, other drugs, and addiction. Working with psychedelics since 2004, he has published over 50 scientific papers on psychedelics. Matt published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He published the first research on psychedelic treatment of tobacco addiction in 2014, and the largest study of psilocybin in cancer distress in 2016. His 2018 psilocybin review recommended Schedule IV upon medical approval. He has guided over 100 psychedelic sessions. Matt also conducts behavioral economic research on both addiction and sexual risk. He conducts research with most psychoactive drug classes, was 2018 President of the Psychopharmacology Division of the American Psychological Association, and is the 2020-2021 President of the International Society for Research on Psychedelics. Interviewed by: 60 Minutes (CBS News), New York Times, Washington Post, Wall Street Journal, BBC, CNN, Fox Business News, NPR, and Michael Pollan.

Dr. Jos Woolley MD/PhD - Scientific Advisor

Dr. Josh Woolley MD/PhD is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF). He is also a licensed psychiatrist on staff at the San Francisco Veterans Affairs Medical Center (SFVAMC). He received both his MD and his PhD in Neuroscience from UCSF and completed his psychiatry residency training at UCSF. Dr. Woolley is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) Laboratory. The mission of the BAND Lab is to understand why people with mental illnesses, including schizophrenia, posttraumatic stress disorder, mood disorders, and substance use disorders, have trouble with social connection, and to develop and test novel treatments for these deficits. His laboratory is actively investigating psilocybin therapy for multiple disorders including major depressive disorder, bipolar depression, chronic pain, and mood symptoms associated with Parkinson's Disease.

Dr. Peter Hendricks, Ph.D. - Scientific Advisor

Dr. Peter Hendricks, Professor in the Department of Health Behavior, University of Alabama at Birmingham is currently researching the use of psilocybin to see if it will help individuals addicted to cocaine stop using the harmful drug. He theorizes that psilocybin, which is the active compound found in Psilocybe mushrooms, also known as "magic mushrooms," can be understood as working from multiple angles, including neurobiological and psychological, with an emphasis on subjective transcendent experiences of awe. Hendricks is able to talk about his research as well as novel and more effective treatments for substance abuse dependence, with specific areas of focus on tobacco, cocaine and polysubstance abuse in vulnerable populations.

As you can see, there are multiple bullish catalysts signaling breakout gain potential!



It’s important to remember that historically, small-cap biotech, biopharmaceutical,

life sciences, nutraceutical and therapeutics companies have been my biggest gainers that are cut from the same cloth as SILO!



I am urging all of our members to add SILO to the top of their watch list right now, and be ready Monday morning at the opening bell!

Sincerely,

Editor In Chief, OTCtipReporter Team

[billionsmatter]

Have a look at this recent newsletter. Ready for your next potential triple digit gainer?

Psychedelic drugs are going mainstream fast, with research supporting their effectiveness in alleviating emotional problems. Scientists continue to revisit different psychedelics such as LSD, magic mushrooms and other therapeutics for a range of mental ailments. Research is in full swing with the announcement from Johns Hopkins on its development of the Center for Psychedelic and Consciousness Research.

I recommend you take a moment and click here and discover how you can get this stock’s name & ticker symbol.

http://www.icontact-archive.com/archive?c=865021&f=14629&s=19386&m=538224&t=06648922036e02f7f04a2684ef5de698b9328bbc84174897a2dc6366aad296b8

If I told you that psychedelic stocks were among some of the best stocks to buy for the next decade, you’d probably look at me funny. I wouldn’t blame you. But, believe it or not, psychedelic stocks are some of the best stocks to buy for the next 10 years. Here is where you need to go now to get the name of this secret stock before everyone else.

This specific secret company is making incredible strides in this sector. It is focused on bringing targeted medicine to market, through novel delivery systems, psychedelic assisted psychotherapy, and Active Pharmaceutical Ingredient grade psilocybin manufacturing. To that effect, while it is still early in the medicinal psychedelic space, hefty valuations are being placed on the most serious contenders competing for a slice of the $100 billion pie.

This Secret Company with a market capitalization of less than $30 million CAD, provides investors with an opportunity which could prove highly lucrative as the industry develops and matures! Just make sure you own a piece of it before it is too late.

Click Here to review a thorough report detailing the above on this "Secret Company" and discover for yourself why you need to invest in it right away!

http://www.icontact-archive.com/archive?c=865021&f=14629&s=19386&m=538224&t=06648922036e02f7f04a2684ef5de698b9328bbc84174897a2dc6366aad296b8

Sincerely,

Editor In Chief, OTCtipReporter Team

[Bcbrasseur]

Gotcha! Good news! Thanks!! I’m new on board starting to stack!

[nuclear profitz]

there was a vote on Jan 12 for a RS...share holders voted against it.

[Bcbrasseur]

? Rs not approved? Could you elaborate please thanks!

[billionsmatter]

This just came out from OTC Tip Reporter Do you see (NASDAQ: AIKI) right now?

As I write this, buyers are coming in during aftermarket trading, note AIKI traded between $1.03 and $1.12 today, and closed at $1.10.

As I write this, I'm watching AIKI trade right now in after-market hours between $1.30 and $1.35/share.

Wednesday could be potentially a gigantic day for AIKI investors.

If you haven't taken a look at this stock yet, this is your chance. AIKI is witnessing a major momentum run.

The Company has several bullish catalysts on the horizon, and is on the verge of disrupting a $176BIL Anti-Cancer Therapeutics Market, and Recent Blockbuster News AIKI Executes Licensing Agreement for Psilocybin for Cancer Applications.

Sincerely,
Editor In Chief, OTCtipReporter Team

[nuclear profitz]

R/S not approved....moving AH

[georgie18]

AIKI...$1.09...Psar flipped to a Bearish Sell Position...Bidding the Open Gap in the .86/$1 range on the Overbought Retrace...

Looking for a dip and rip as the 50/20 cross sets up here...Money Flow / Accumulation Line Confirm a Gap Fill... imo...we shall see...

Chart...https://schrts.co/uZfFyNwA

[Taurus69]

$aiki $1.09 v -0.09 (-7.63%)
Volume: 4,417,605 @01/15/21 7:59:56 PM EST

[sanscuba]

AIKI may open up at 1.60 tomorrow. Something brewing
Holding FDIT BBRW EDXC for a nice major run to come

[AlphaStockNews]

$SILO climbs on agreement with $AIKI https://cnafinance.com/silo-stock-silo-pharma-inks-a-1-million-agreement-with-aiki/

[cjstocksup]

4K I love it there should be many more large buyers ahead in more 4k's.
LeMire Paul 2. Issuer Name and Ticker or Trading Symbol Aikido Pharma Inc. [ AIKI ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
ONE ROCKEFELLER PLAZA, 11TH FLOOR 3. Date of Earliest Transaction (MM/DD/YYYY)
12/23/2020

They bought 50K shares of AIKI